Back to search results

Digital Treatment for Chronic Pain and Opioid Use Disorder in Veterans

This study is looking at a new way to help Veterans who have both chronic pain and opioid use disorder (OUD), and are currently taking buprenorphine. It compares a web-based program called Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) with standard care (Enhanced Treatment as Usual or ETAU) offered at VA clinics. IMPACT is a 9-module online program with weekly feedback from a coach. We want to see if IMPACT helps reduce how much pain interferes with your daily life after 3 months. You might be able to join if you're a Veteran aged 18 or older with an OUD diagnosis and are on a stable dose of buprenorphine. The study plans to enroll 250 participants, but its current recruitment status is unclear.

Study design
This is an interventional study comparing two behavioral treatments: the IMPACT web-based program and Enhanced Treatment as Usual (ETAU). It plans to enroll 250 participants.
What's involved
The IMPACT program involves 9 weeks of web-based treatment with daily digital surveys and weekly feedback. The ETAU group receives medication management, groups, and individual treatment at VA clinics.
Compensation
Not stated in the trial record.
Follow-up
Your pain interference will be measured 3 months after you are assigned to a treatment group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07361432

Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine

Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatment
VA Office of Research and Development
~250 participants
Updated 2026-01-28 on ClinicalTrials.gov
What's tested:Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT)Enhanced Treatment as Usual (ETAU)

At a glance

Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PROMIS Pain Interference 6b
Measured over 3-months post-randomization

Conditions

Opioid Use Disorder
Chronic Pain

Explore related trials

Chronic PainOpioid Use Disorder

Where it's being run

4 sites across 3 states
Massachusetts2
Connecticut1
Oregon1

Study leadership

  • R. Ross MacLean, PhD · PRINCIPAL_INVESTIGATOR · VA Connecticut Healthcare System West Haven Campus, West Haven, CT

Who to contact

R. Ross MacLean, PhD
[email protected]
(203) 932-5711 · ext. 7423
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

an ICD-11 OUD diagnosis in the VHA electronic health record (EHR)
receipt of buprenorphine from outpatient addiction clinic with stable (i.e., unchanged in 2 weeks or since last injection) dose confirmed by the prescribing clinician. Both oral and injectable buprenorphine formulations will be eligible with dose stabilization required to isolate chronic pain from withdrawal-related pain associated with non-therapeutic dose
presence of musculoskeletal pain that is bothersome or high-impact per the Graded Pain Scale - Revised
access to a web-connected device to complete daily surveys and connect to IMPACT treatment site
ability to participate safely in the walking portion of the intervention as evidenced by patient-reported ability to walk at least one block

Exclusion

dementia-related EHR diagnosis
participant-reported vision or hearing impairments that would preclude use of the IMPACT system
legal actions that would make study completion unlikely
current or past 12 month engagement in CBT for chronic pain treatment
planned surgical intervention for pain
physical or mental health conditions that would interfere with ability to meaningful engage in IMPACT and MOUD treatment (e.g., uncontrolled bipolar disorder, active suicidal ideation, receipt of hospice or end-of-life palliative care)

What this trial measures

  • PROMIS Pain Interference 6b3-months post-randomization

    T-score will be calculated from raw scores with a mean of 50 and standard deviation of 10 (lower corresponds to less pain interference).